LBPMedicine(SH:688393) 智通财经网·2026-02-27 10:58Core Viewpoint - Anbipin (688393.SH) reported a significant decline in its 2025 annual performance, with total operating revenue of 347 million yuan, a year-on-year decrease of 26.24%, and a net profit loss of 44.97 million yuan, shifting from profit to loss [1] Group 1: Financial Performance - The total operating revenue for 2025 was 347 million yuan, reflecting a 26.24% year-on-year decline [1] - The net profit attributable to the parent company was a loss of 44.97 million yuan, indicating a shift from profit to loss compared to the previous year [1] Group 2: Business Impact Factors - The implementation of national centralized procurement policies led to a significant price drop in the company's HPV product line, resulting in a revenue decrease of approximately 46.5 million yuan [1] - The company proactively optimized its business structure by focusing on the expansion of core business revenue and reducing the scale of agency product business [1] Group 3: Strategic Adjustments - To accelerate market penetration, the company actively adjusted its channel strategy, increasing the proportion of distribution channels [1] - The sales price of products decreased year-on-year, which had a short-term impact on overall gross profit [1]